Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective: To characterize the initial presentation and clinical course of patients with hepatocyte nuclear factor (HNF) 4A‒ and HNF1B‒MODY in a multinational registry. Design, Setting, and Participants: Within the Diabetes Patienten Verlaufsdokumentation (DPV) registry, 44 patients with HNF4A- and 35 patients with HNF1B-MODY were characterized and compared with patients <20 years old with type 1 diabetes (T1D)/type 2 diabetes (T2D). Main Outcome Measure: Clinical and laboratory parameters, therapy, metabolic control, and extrapancreatic symptoms in patients with HNF1B-MODY. Results: Patients with both MODY types were significantly older than patients with T1D at diagnosis (HNF4A, 13.8 years, and HNF1B, 13.5 years, vs T1D, 8.8 years; P < 0.0001). Mean C-peptide at diagnosis was higher for HNF4A-MODY than for T1D (1.8 vs 0.9 ng/mL; P < 0.01); 36.4% of patients with HNF4A-MODY and 65.7% of patients with HNF1B-MODY were treated with insulin, whereas 20.5% and 8.6% received oral antidiabetics only (P < 0.05 and P < 0.01 vs T2D). At the most recent visit, glycated hemoglobin levels were lower in HNF4A- and HNF1B-MODY (mean, 6.5% and 6.1%) than in T1D (7.9%; P < 0.0001). In 40% of patients with HNF1B-MODY, extrapancreatic symptoms were reported. Several clinical predictors previously described to differentiate between MODY and T1D or T2D were revalidated by logistic regression analyses in this cohort. Conclusion: The DPV registry enabled us to precisely characterize phenotype and treatment in these two rare MODY types. Although phenotype of HNF4A- and HNF1B-MODY showed distinct differences from those of T1D and T2D, 38% of patients were initially misclassified as having T1D or T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are 14 genes that have been implicated as causes of MODY accounting for 11 different types of MODY.48,49”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [48]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Smoothing reference centile curves: The lms method and penalized likelihood
Cole, T. J., & Green, P. J. (1992) · Statistics in Medicine · doi:10.1002/sim.4780111005 · Cited by 2,781
Kromeyer-Hauschild, K., Wabitsch, M., Kunze, D., Geller, F., Geiß, H. C., Hesse, V., von Hippel, A., Jaeger, U., Johnsen, D., Korte, W., et al. (2001) · Monatsschrift Kinderheilkunde · doi:10.1007/s001120170107 · Cited by 2,175
Yates, A., Akanni, W., Amode, M. R., Barrell, D., Billis, K., Carvalho-Silva, D., Cummins, C., Clapham, P., Fitzgerald, S., Gil, L., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1157 · Cited by 1,273
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Maturity-onset diabetes of the young (MODY): how many cases are we missing?
Shields, B. M., Hicks, S., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Ellard, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1799-4 · Cited by 725
Genetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Clinical implications of a molecular genetic classification of monogenic β-cell diabetes
Murphy, R., Ellard, S., & Hattersley, A. T. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0778 · Cited by 502
Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young
Ellard, S., Bellanné-Chantelot, C., Hattersley, A. T., & European Molecular Genetics Quality Network (EMQN) MODY group (2008) · Diabetologia · doi:10.1007/s00125-008-0942-y · Cited by 433
Pihoker, C., Gilliam, L. K., Ellard, S., Dabelea, D., Davis, C., Dolan, L. M., Greenbaum, C. J., Imperatore, G., Lawrence, J. M., Marcovina, S. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1279 · Cited by 397
Research works printed but not linked: 2
- Glaser, 2003, GeneReviews®. Seattle (WA), 1993
- Schlebusch, 2008, POCT 2008. Patientennahe Labordiagnostik, 55
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00112-5 · Cited by 178
Update on clinical screening of maturity-onset diabetes of the young (MODY)
Peixoto-Barbosa, R., Reis, A. F., & Giuffrida, F. M. A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00557-9 · Cited by 116
Low, B. S. J., Lim, C. S., Ding, S. S. L., Tan, Y. S., Ng, N. H. J., Krishnan, V. G., Ang, S. F., Neo, C. W. Y., Verma, C. S., Hoon, S. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22843-4 · Cited by 85
Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling
Skoczek, D., Dulak, J., & Kachamakova‐Trojanowska, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147553 · Cited by 48
“On the other hand, in a study which screened diabetic patients under the age of 20, it was showed that 10% of all HNF4A-MODY cases present dyslipidaemia [118].”
BackgroundPrecision treatment of beta-cell monogenic diabetes: a systematic review
Naylor, R. N., Patel, K., Kettunen, J. L. T., Männistö, J. M. E., Støy, J., Beltrand, J., Polak, M., PMDI, A., Tobias, D. K., Merino, J., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00556-1 · Cited by 46
Stankutė, I., Verkauskienė, R., Blouin, J., Klee, P., Dobrovolskienė, R., Danytė, E., Dirlewanger, M., Santoni, F. A., Ražanskaitė-Virbickienė, D., Marčiulionytė, D., et al. (2020) · Diabetes · doi:10.2337/db19-0974 · Cited by 34
“Recent data from a pediatric multinational registry show that 38% ofHNF4A andHNF1B diabetes are misclassified as type 1 or 2 diabetes (8).”
BackgroundChemical Starting Matter for HNF4α Ligand Discovery and Chemogenomics
Meijer, I., Willems, S., Ni, X., Heering, J., Chaikuad, A., & Merk, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217895 · Cited by 30
“Its dysregulation has been associated with gastrointestinal and metabolic diseases [5,10,11] as well as gastrointestinal cancers [5,12,13].”
BackgroundHu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 27
Sztromwasser, P., Michalak, A., Małachowska, B., Młudzik, P., Antosik, K., Hogendorf, A., Zmysłowska, A., Borowiec, M., Mlynarski, W. M., & Fendler, W. M. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12959 · Cited by 24
“Autosomal dominant mutations in HNF1B cause up to 1%-2% of MODY cases.(3,4) Pathogenic single nucleotide substitutions, indels, and exon deletions in HNF1B comprise about half of findings in patients with HNF1B-MODY.”
BackgroundMagnesium Homeostasis: Lessons from Human Genetics
Morrison, A. R. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000103 · Cited by 19
Özsu, E., Çetinkaya, S. Ç., Bolu, S., Hatipoğlu, N., Erdeve, Ş. S., Evliyaoğlu, O., Baş, F., Çayır, A., Dündar, İ., Akbaş, E. D., et al. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2023-10-16 · Cited by 18
“In the largest series from Germany/Austria, MODY1 was found in 44, MODY2 in 609, MODY3 in 230, and MODY5 in 35 of 1047 MODY cases from 76,836 children under 20 years of age with diabetes (12).”
Lee, S., Veeriah, V., & Levine, F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266066 · Cited by 17
“However, its role in other organs where it is expressed, including the pancreatic islet [5, 6], and the kidney [7–9], its role varies considerably.”
BackgroundNext Generation Sequencing Analysis of MODY-X Patients: A Case Report Series
Maltoni, G., Franceschi, R., Natale, V. D., Alqaisi, R. S., Greco, V., Bertorelli, R., Sanctis, V. D., Quattrone, A., Mantovani, V., Cauvin, V., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101613 · Cited by 17
“Extra-pancreatic symptoms have been reported in 40% of patients with HNF1B-MODY in the DPV database [32].”
BackgroundMonogenic diabetes: An evidence-based clinical approach
Bhattacharya, S., Fernandez, C. J., Kamrul-Hasan, A. B. M., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.104787 · Cited by 18
“According to a multinational registry from four European countries, the median age of diagnosis is 13.8 years for HNF4A -MODY and 13.5 years for HNF1B -MODY[42].”
InfluentialZhou, Q., Samadli, S., Zhang, H., Zheng, X., Zheng, B., Zhang, A., & Gu, W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae779 · Cited by 16
Deletion of Jazf1 gene causes early growth retardation and insulin resistance in mice
Lee, H., Jang, H. R., Li, H., Samuel, V. T., Dudek, K. D., Osipovich, A. B., Magnuson, M. A., Sklar, J., & Shulman, G. I. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213628119 · Cited by 14
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
“…less prevalent than these main types of diabetes and, in them, nephropathy is infrequent, but Maturity ‐ onset diabetes of the young (MODY) 5 due to HNF ‐ 1beta mutations is associated with renal disease, 12 these mutations show > 95% penetrance at 40 years of age and cause beta cell dysfunction.”
BackgroundMolecular dissection of the role of ACE2 in glucose homeostasis
Chhabra, K. H., Shoemaker, R., Herath, C. B., Thomas, M. C., Filipeanu, C. M., & Lazartigues, E. D. (2025) · Physiological Reviews · doi:10.1152/physrev.00027.2024 · Cited by 10
Thorough statistical analyses of breast cancer co-methylation patterns
Sun, S., Dammann, J., Lai, P., & Tian, C. (2022) · BMC Genomic Data · doi:10.1186/s12863-022-01046-w · Cited by 8
Cost–effectiveness of Genetic-Based Screening Strategies for Maturity-Onset Diabetes of the Young
Kovács, G., Nagy, D., Szilberhorn, L., Zelei, T., Gaál, Z., Vellekoop, H., Huygens, S. A., Versteegh, M., Mölken, M. R., Koleva‐Kolarova, R., et al. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0023 · Cited by 8
Song, X., Cao, Y., Ye, J., Dai, W., Zhang, S., & Ye, S. (2022) · Medicine · doi:10.1097/md.0000000000030668 · Cited by 7
“Currently, the commonly used diagnostic criteria for MODY are: at least 1 to 2 patients in the family have a disease onset before the age of 25; at least 3 consecutive generations of autosomal dominant inheritance; generally no insulin treatment required within 5 years after diagnosis; β-cell dysfunction.[9,10] The cl…”
MethodNg, N., Zamuner, M. B. M., Siddique, N., Kim, J. M., Burke, M., & Byrne, M. M. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01794-8 · Cited by 8
Review of Monogenic Diabetes: Clinical Features and Precision Medicine in Genetic Forms of Diabetes
Cobry, E. C., & Steck, A. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0602 · Cited by 6
“42,44 Age of onset of hyperglycemia is often in adolescents through mid-twenties; however, due to the presence of other developmental abnormalities and the varying degree of expression, diagnosis may occur shortly after birth or into middle age.”
International expert consensus on surgery for type 2 diabetes mellitus
Kermansaravi, M., Omar, I., Finer, N., le Roux, C. W., Carbajo, M. A., Sarwer, D. B., Busetto, L., Ponce, J., Logue, J., Parretti, H. M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01961-w · Cited by 7
Hohendorff, J., Zapała, B., Ludwig‐Słomczyńska, A. H., Solecka, I., Ucieklak, D., Matejko, B., Mrozińska, S., Malecki, M. T., & Szopa, M. (2020) · Minerva Medica · doi:10.23736/s0026-4806.19.06053-1 · Cited by 6
Early Onset of Mody5 Due to Haploinsufficiency of HNF1B
Bustamante, C., Sanchez, J. E., Seeherunvong, T., & Ukarapong, S. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0161 · Cited by 6
“Most patients with MODY5 required insulin therapy at the time of the diagnosis (5).”
BackgroundDiabetes im Kindes- und Jugendalter: Prävalenz und Inzidenz in Deutschland
Stahl‐Pehe, A., Holl, R. W., & Rosenbauer, J. (2025) · Kinder- und Jugendmedizin · doi:10.1055/a-2504-5477 · Cited by 5
Self-citationVourdoumpa, A., Paltoglou, G., Mertzanian, A., Sertedaki, A., Sakou, I.-I., Karanasios, S., Karavanaki, K., & Charmandari, E. (2024) · HORMONES · doi:10.1007/s42000-024-00580-9 · Cited by 5
“One of the rarest forms is HNF1B MODY (MODY5), which accounts for ≤ 5% of MODY cases [2, 3].”
Vlachopapadopoulou, E. A., Dikaiakou, E., Fotiadou, A., Sifianou, P., Tatsi, E., Sertedaki, A., Kanaka‐Gantenbein, C., & Michalacos, S. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0302 · Cited by 5
Aydın, C., Kıral, E., Susam, E., Tufan, A. K., Yarar, Ç., Çetin, N., Kocagil, S., & Kırel, B. (2022) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2021.1613 · Cited by 4
Szilberhorn, L., Zelei, T., Vellekoop, H., Huygens, S. A., Versteegh, M., Mölken, M. R., Koleva‐Kolarova, R., Tsiachristas, A., Wordsworth, S., & Nagy, B. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0017 · Cited by 3
Pediatric Hepatocyte Nuclear Factor 1B ( HNF1B ) Disease: Diabetes and Endocrine Manifestations
Craven, M., Bamba, V., Calabria, A. C., & Pinney, S. E. (2025) · Pediatric Diabetes · doi:10.1155/pedi/4077604 · Cited by 2
“Cohorts described by Warncke et al. [3] and Sztromwasser et al. [21] were recruited from diabetes patient registries similar to the CHOP HNF1B disease cohort.”
Guzmán, G. E., Madariaga, I., Vargas-Potes, C. J., Ballen, L. J., Guerra, M. A., & Nastasi-Catanese, J. A. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03873-6 · Cited by 2
“This suggests that pathogenic mutations of HNF1B cause an earlier or more severe impairment of insulin secretion than mutations in the HNF4A gene [13].”
BackgroundDüzkale, N., & Emiroğlu, C. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0030 · Cited by 3
“Hypomagnesemia, hypokalemia, hypocalciuria, hepatic dysfunction, microvascular complications, and low birth weight have been reported in these patients [20].”
BackgroundTransition bei komplexen endokrinologischen und diabetologischen Erkrankungen
Kiewert, C., Führer, D., & Unger, N. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01927-z · Cited by 1
Diabetes mellitus HNF4A-MODY in children from the Russian population: clinical and genetic features
Sechko, E. A., Лаптев, Д. Н., Koltakova, M. P., Khusainova, R. I., Minniakhmetov, I. R., Кураева, Т. Л., Eremina, I. A., Титович, Е. В., Bezlepkina, O. B., & Peterkova, V. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1673182 · Cited by 1
Monogener Diabetes - die Kunst ist das Erkennen
Kapellen, T. M. (2020) · Info Diabetologie · doi:10.1007/s15034-020-2158-2 · Cited by 1
“Weitere Publikationen aus der DPV-Datenbank zu seltenen Diabetesformen folgten [4, 5, 6].”
BackgroundInfluentialHNF1B variant without hyperglycaemia as a cause of isolated profound hypomagnesaemia
Vollmer, S., Katzman, P., & Löndahl, M. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-254274 · Cited by 1
Papizh, S., & Piruzieva, O. R. (2019) · Nephrology (Saint-Petersburg) · doi:10.24884/1561-6274-2019-23-2-100-108
Nicht immer Typ 1 – seltene Diabetesformen bei Kindern
Warncke, K. (2021) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-021-01238-1
“(Adaptiert nach Hattersley et al. [2]) MODYTyp Gen Klinische Besonderheiten Behandlung Referenz 1 HNF4A Neonatale Hypoglykämiemöglich Sulfonylharnstoffe [12] 2 GCK Milde asymptomatischeHyperglykämie Keine, ggf. Diät [13] 3 HNF1A Renale Glucosurie Sulfonylharnstoffe [14] 5 HNF1B Nierenzysten, Malfomationen im Uro- geni…”
BackgroundSelf-citationKarakılıç, E., Saygılı, E. S., Sılan, F., Öndüç, G. G., & Agcaoglu, U. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-01027-2
“MODY type 1 cases were generally diagnosed in the young adult period, progressed over time, and may require multiple OAD or insulin treatments [30].”
BackgroundСолнцева, А. В., & Беляева, Е. А. (2022) · Педиатрия Восточная Европа · doi:10.34883/pi.2022.10.2.009
Precision Genetics for Monogenic Diabetes
Luk, A. O. Y., & Lim, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_6
[Rare causes of abnormal liver function in a case of renal cysts and diabetes syndrome].
Wang, Z., Hou, W., & Zheng, S. (2023) · PubMed Central · doi:10.3760/cma.j.cn501113-20230619-00267
Abbasi, M. Z. I., Unnikrishnan, A., & Radha, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00003-6
Can standard CGM data be used to identify an HNF1B MODY-5 glucotype? Insights from a clinical case
Oriot, P., kurz, N. K. D., & Hermans, M. P. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.10.002
Transition bei komplexen endokrinologischen und diabetologischen Erkrankungen
Kiewert, C., Führer, D., & Unger, N. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02213-w
Hodgson, S., Bui, V., Hu, S., Maroteau, C., Bigossi, M., Huerta‐Chagoya, A., Nguyen, T., Dawed, A. Y., Koesterer, R., Vora, M., et al. (2025) · medRxiv · doi:10.1101/2025.09.24.25336527
Vastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8076420/v1
Beyazıt, Y., Ertekin, Y. H., Kurtkulağı, Ö., & Pek, E. (2024) · doi:10.55094/holistence.237
Additional file 1 of Thorough statistical analyses of breast cancer co-methylation patterns
Sun, S., Dammann, J., Lai, P., & Tian, C. (2022) · Figshare · doi:10.6084/m9.figshare.19607692
Agrawal, N., Chakraborty, P. P., Bhattacharjee, R., Roy, A., & Maiti, A. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01626-x
Metadata
- Authors
- Warncke, K., Kummer, S., Raile, K., Grulich-Henn, J., Woelfle, J., Steichen, E., Prinz, N., & Holl, R. W.
- Affiliations
- TUM Klinikum (DE)
- Düsseldorf University Hospital (DE)
- Stiftung Charité (DE)
- Department of Pediatrics, University of Heidelberg, Heidelberg, Germany
- University of Bonn (DE)
- Innsbruck Medical University (AT)
- Universität Ulm (DE)
- Corresponding author
- Warncke, Katharina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-12-10
- Volume
- 104
- Issue
- 3
- Pages
- 845-855
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2905492527
- Cited by
- 52
- References
- 41
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 5 · 2020: 9 · 2019: 2
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- green
- nbn-resolving.de
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Universität Ulm, Kommunikations- und Informationszentrum (kiz)
- Funders
- Federal Ministry of Education and Research within the German Center for Diabetes Research (82DZD0017G)
- INNODIA, supported by the European Union’s Horizon 2020 research and innovation program and “EFPIA”, ‘JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust (115797)
- Deutsche Diabetes Gesellschaft
- Robert Koch Institut
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- HNF4A mutations, HNF1B mutations, hepatocyte nuclear factor, monogenic diabetes, HbA1c, insulin therapy, C-peptide, DPV registry, clinical phenotype
- MeSH terms
- Adolescent, Age Factors, Child, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diagnosis, Differential, Female, Humans, Hypoglycemic Agents, Insulin, Male, Prospective Studies, Registries, Rare Diseases, Hepatocyte Nuclear Factor 1-beta, Hepatocyte Nuclear Factor 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.